Latest Conference Articles

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.

Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.

Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.

Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.

CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.

Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.

Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.

Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.

Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.

Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.